Source comparison
Titration Protocols: Loading Phase vs Maintenance Dosing
Standard research protocols divide Melanotan-2 administration into two distinct phases with different dosing logic. The loading phase establishes baseline receptor saturation and triggers initial melanogenesis. This requires daily or near-daily dosing at 0.25m
This comparison does not assign a generated winner or score.
- Standard research protocols divide Melanotan-2 administration into two distinct phases with different dosing logic. The loading phase establishes baseline receptor saturation and triggers initial melanogenesis. This requires daily or near-daily dosing at 0.25mg to 0.5mg for 7–14 days depending on subject baseline pigmentation and tolerance to side effects. Subjects with Fitzpatrick Type I skin (very fair, always burns) typically require 10–14 days at the lower end of the range, while Type III–IV subjects may achieve target pigmentation within 7–10 days at 0.5mg daily.
- Maintenance dosing shifts to 2–3 administrations per week once visible pigmentation develops, with individual doses ranging from 0.5mg to 1mg depending on the desired pigmentation depth and subject-specific response. The biological rationale: melanin synthesis, once initiated, persists for 48–72 hours after a single Melanotan-2 dose due to sustained elevation of tyrosinase enzyme activity and continued melanocyte proliferation. Daily dosing during maintenance is unnecessary and increases side effect burden without proportional efficacy gains.
- Common titration error: starting at 1mg on day one. Melanocortin receptor density in naive subjects is insufficient to handle high initial doses. The result is severe nausea, spontaneous erections (in male subjects due to MC4R activation), and facial flushing lasting 2–4 hours post-injection. These effects diminish significantly with slow upward titration as receptor density adapts. A properly designed protocol starts at 0.25mg, assesses tolerance over 2–3 days, then increases to 0.5mg if no prohibitive side effects occur. Rushing this phase is the single most common cause of protocol abandonment in research settings.